The role of hepatitis B vaccine challenge dose in patients with underlying health conditions

References

• Grazzini M, Arcangeli G, Mucci N, Bonanni P, Bini C, Bechini A, Boccalini S, Tiscione E, Paolini D. High chance to overcome the non-responder status to hepatitis B vaccine after a further full vaccination course: results from the extended study on healthcare students and workers in Florence, Italy. Hum Vaccin Immunother. 2020;16(4):949–54. doi:10.1080/21645515.2019.1680082.
   PubMed Web of Science ®Google Scholar
• Dini G, Toletone A, Barberis I, Debarbieri N, Massa E, Paganino C, Bersi F, Montecucco A, Alicino C, Durando P. Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy. Hum Vaccin Immunother. 2017 Feb;13(2):440–44. doi:10.1080/21645515.2017.1264788.
   PubMed Web of Science ®Google Scholar
• Stefanati A, Bolognesi N, Sandri F, Dini G, Massa E, Montecucco A, Lupi S, Gabutti G. Long-term persistency of hepatitis B immunity: an observational cross-sectional study on medical students and resident doctors. J Prev Med Hyg. 2019 Sep 30;60(3):E184–E190. doi:10.15167/2421-4248/jpmh2019.60.3.1315.
   PubMedGoogle Scholar
• Italian Ministry of Health. National immnunization prevention plan 20172019. Published on the Italian Official Gazette; 2017 February 18 [accessed 2020 Mar 31]. http://www.gazzettaufficiale.it/eli/id/2017/02/18/17A01195/sg
   Google Scholar
• Nicolini LA, Magne F, Signori A, Di Biagio A, Sticchi L, Paganino C, Durando P, Viscoli C. Hepatitis B virus vaccination in HIV: immunogenicity and persistence of seroprotection up to 7 years following a primary immunization course. AIDS Res Hum Retroviruses. 2018 Nov;34(11):922–28. doi:10.1089/aid.2017.0070.
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of viral hepatitis and HIV coinfection. J Hepatol. 2006;44:S6–S9. doi:10.1016/j.jhep.2005.11.004.
   PubMed Web of Science ®Google Scholar
• Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD for the EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS Lond Engl. 2005;19:593–601. doi:10.1097/01.aids.0000163936.99401.fe.
   PubMed Web of Science ®Google Scholar
• Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet. 2002;360:1921–26. doi:10.1016/S0140-6736(02)11913-1.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-infected adult: a review of the current recommendations, part I. Infect Dis Ther. 2017;6(3):303–31. doi:10.1007/s40121-017-0166-x.
   PubMedGoogle Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2013;2014(58):309–18.
   Google Scholar
• van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev. 2009;11:157–64.
   PubMed Web of Science ®Google Scholar
• Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS. 2009;20:595–600. doi:10.1258/ijsa.2009.009126.
   PubMed Web of Science ®Google Scholar
• Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988;109:101–05. doi:10.7326/0003-4819-109-2-101.
   PubMed Web of Science ®Google Scholar
• Paitoonpong L, Suankratay C. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis. 2008;40:54–58. doi:10.1080/00365540701522975.
   PubMed Web of Science ®Google Scholar
• Pasricha N, Datta U, Chawla Y, Singh S, Arora SK, Sud A, Minz RW, Saikia B, Singh H, James I, et al. Immune responses in patients with HIV infection after vaccination with recombinant hepatitis B virus vaccine. BMC Infect Dis. 2006;6:65. doi:10.1186/1471-2334-6-65.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore A, Bell B, Hennessy T, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390–96. doi:10.1086/606119.
   PubMed Web of Science ®Google Scholar
• Lopes VB, Hassing RJ, de Vries-sluijs TE, El Barzouhi A, Hansen BE, Schutten M, de Man RA, van der Ende ME. Longterm response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31:1040–44. doi:10.1016/j.vaccine.2012.12.047.
   PubMed Web of Science ®Google Scholar
• Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, Peel S, Agan BK. Hepatitis B vaccine responses in a large US military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine. 2009;27:4731–38. doi:10.1016/j.vaccine.2009.04.016.
   PubMed Web of Science ®Google Scholar
• Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12:966–76. doi:10.1016/S1473-3099(12)70243-8.
   PubMed Web of Science ®Google Scholar
• Okulicz JF, Mesner O, Ganesan A, O’Bryan TA, Deiss RG, Agan BK. Hepatitis B vaccine responsiveness and clinical outcomes in HIV controllers. PLoS One. 2014;9:1–8. doi:10.1371/journal.pone.0105591.
   Web of Science ®Google Scholar
• Abzug MJ, Warshaw M, Rosenblatt HM, Levin M, Nachman S, Pelton S, Borkowsky W, Fenton T. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2009;200:935–46. doi:10.1086/605448.
   PubMed Web of Science ®Google Scholar
• Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, Dhanireddy S, Baeten JM. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis. 2013 Feb 1;207(3):402–10. doi:10.1093/infdis/jis695.
   PubMed Web of Science ®Google Scholar
• Keet IP, van Doornum G, Safary A, Coutinho RA. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS. 1992;6:509–10.
   PubMed Web of Science ®Google Scholar
• Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, Wendling MJ, Vetter D, Nicolle M, Kempf-Durepaire G, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects HIV-1 Viral Load Vacc. 2000;18:1161–65.
   Google Scholar
• De Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz N, de Man R, van der Ende M. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis. 2008;197:292–94. doi:10.1086/524690.
   PubMed Web of Science ®Google Scholar
• Psevdos G, Kim JH, Groce V, Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS. 2010;24:403–07. doi:10.1089/apc.2009.0340.
   PubMed Web of Science ®Google Scholar
• Rey D, Piroth L, Wendling MJ, Miailhes P, Michel M-L, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, ANRS HB04 B–BOOST study group, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015;15:1283–91. doi:10.1016/S1473-3099(15)00220-0.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, Rimondo C, Bricolo F, Consolaro S, Trevisan M, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of infections in HIV infected adult patients. Vaccine. 2009;27:17–22. doi:10.1016/j.vaccine.2008.10.040.
   PubMed Web of Science ®Google Scholar
• Aggeletopoulou I, Davoulou P, Konstantakis C, Thomopoulos K, Triantos C. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol. 2017;27(6):e1942. doi:10.1002/rmv.1942.
   Web of Science ®Google Scholar
• Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;2013:196704. doi:10.1155/2013/196704.
   PubMedGoogle Scholar
• Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol. 2000;14(Suppl B):59b‐62b. doi:10.1155/2000/548206.
   Google Scholar
• Engler SH, Sauer PW, Golling M, Klar EA, Benz C, Stremmel W, Kallinowski B. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol. 2001;13:363‐367. doi:10.1097/00042737-200104000-00010.
   PubMed Web of Science ®Google Scholar
• Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc. 1998;30:797‐799. doi:10.1016/S0041-1345(98)00053-0.
   PubMed Web of Science ®Google Scholar
• Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double‐dose accelerated hepatitis B vaccine in patients with end‐stage liver disease. Liver Transpl. 2001;7:314‐320. doi:10.1053/jlts.2001.23069.
   PubMed Web of Science ®Google Scholar
• Bonazzi PR, Bacchella T, Freitas AC, Osaki KT, Lopes MH, Freire MP, Machado MCC, Abdala E. Double‐dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis. 2008;12:306‐309. doi:10.1590/S1413-86702008000400009.
   PubMed Web of Science ®Google Scholar
• Mast EE, Weinbaum CM, Fiore AE, Burton N, Cox-Ganser J, Damon S, Falk H, Fridkin S, Garbe P, McGeehin M, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55:1‐33.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine‐preventable diseases. Washington (DC): Public Health Foundation; 2011. p. 12.
   Google Scholar
• Manser CN, Maillard MH, Rogler G, Schreiner P, Rieder F, Bühler S Vaccination in patients with inflammatory bowel diseases. Digestion. 2020 Jan 22 2020:1–11. [published online ahead of print].
   Google Scholar
• Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, Koval C, Lease ED, Pillai A, Doucette KE, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015 May;15(5):1162–72. doi:10.1111/ajt.13187.
   PubMed Web of Science ®Google Scholar
• Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect. 2012;18(Suppl 5):93–99. doi:10.1111/j.1469-0691.2012.03971.x.
   PubMedGoogle Scholar
• Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, Lumeng L, Chalasani N. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999;318:304–07. doi:10.1016/S0002-9629(15)40643-3.
   PubMed Web of Science ®Google Scholar